Bionical Emas launches Managed Access Program for JZP 458 – a recombinant Crisantaspase produced in Pseudomonas fluorescens
G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States
Four things to think about: PVG in EAPs
By Nisha Vora - Senior Project Manager, Pharmacovigilance
Nuances in Pharmacovigilance case processing in Early Access Programs
By Harry Woods - Pharmacovigilance Associate
What does Early Access actually mean?
Naomi Litchfield, Patient Advocacy Manager for Bionical Emas, discusses the basic principles of Early Access Programs